These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26159375)

  • 21. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
    Iio E; Shimada N; Abe H; Atsukawa M; Yoshizawa K; Takaguchi K; Eguchi Y; Nomura H; Kuramitsu T; Kang JH; Matsui T; Hirashima N; Tsubota A; Kusakabe A; Hasegawa I; Miyaki T; Shinkai N; Fujiwara K; Nojiri S; Tanaka Y
    J Gastroenterol; 2017 Jan; 52(1):94-103. PubMed ID: 27236547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
    Poordad F; Sievert W; Mollison L; Bennett M; Tse E; Bräu N; Levin J; Sepe T; Lee SS; Angus P; Conway B; Pol S; Boyer N; Bronowicki JP; Jacobson I; Muir AJ; Reddy KR; Tam E; Ortiz-Lasanta G; de Lédinghen V; Sulkowski M; Boparai N; McPhee F; Hughes E; Swenson ES; Yin PD;
    JAMA; 2015 May; 313(17):1728-35. PubMed ID: 25942723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
    Morio K; Imamura M; Kawakami Y; Morio R; Kobayashi T; Yokoyama S; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Makokha GN; Hayes CN; Aikata H; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
    J Gastroenterol Hepatol; 2017 Mar; 32(3):645-650. PubMed ID: 27513614
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of simeprevir with daclatasvir for non-cirrhotic genotype-1b-naïve patients plus chronic hepatitis C.
    Gimeno-Ballester V; Mar J; San Miguel R
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):285-94. PubMed ID: 26327360
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile.
    Vargas CL; Espinoza MA; Giglio A; Soza A
    PLoS One; 2015; 10(11):e0141660. PubMed ID: 26544203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.
    Oh JY; Kim BS; Lee CH; Song JE; Lee HJ; Park JG; Hwang JS; Chung WJ; Jang BK; Kweon YO; Tak WY; Park SY; Jang SY; Suh JI; Kwak SG
    Korean J Intern Med; 2019 Jul; 34(4):794-801. PubMed ID: 29792020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
    Koshino K; Ushigome H; Masuda K; Matsuyama T; Harada S; Nakamura T; Nobori S; Iida T; Yoshimura N
    Transplant Proc; 2017 Jun; 49(5):1053-1055. PubMed ID: 28583525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
    Ahmed AM; Doheim MF; Mattar OM; Sherif NA; Truong DH; Hoa PTL; Hirayama K; Huy NT
    J Med Virol; 2018 May; 90(5):907-918. PubMed ID: 28892235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.
    Ueno T; Osawa M; Imai Y; Ishikawa H; Garimella T
    J Clin Pharmacol; 2018 Nov; 58(11):1479-1488. PubMed ID: 30063245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
    Swallow E; Kelley C; Signorovitch J; Wygant G; McPhee F
    J Comp Eff Res; 2016 May; 5(3):273-9. PubMed ID: 26793987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
    Kinugasa H; Ikeda F; Takaguchi K; Mori C; Matsubara T; Shiraha H; Takaki A; Iwasaki Y; Toyooka S; Yamamoto K
    Antivir Ther; 2016; 21(1):37-44. PubMed ID: 26115551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
    Yu ML
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.
    Lee HW; Oh SR; Kim DY; Jeong Y; Kim S; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH; Park JY
    Gut Liver; 2018 May; 12(3):324-330. PubMed ID: 29409309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.
    Thiam A; Conway B
    Drugs Today (Barc); 2018 Apr; 54(4):237-244. PubMed ID: 29869645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study.
    Kawakami Y; Imamura M; Ikeda H; Suzuki M; Arataki K; Moriishi M; Mori N; Kokoroishi K; Katamura Y; Ezaki T; Ueno T; Ide K; Masaki T; Ohdan H; Chayama K
    J Viral Hepat; 2016 Nov; 23(11):850-856. PubMed ID: 27346670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China.
    Chen P; Ma A; Liu Q
    Clin Drug Investig; 2018 Nov; 38(11):1031-1039. PubMed ID: 30194584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
    Morisawa N; Koshima Y; Satoh JI; Maruyama Y; Kuriyama S; Yokoo T; Amemiya M
    Clin Exp Nephrol; 2017 Oct; 21(5):818-824. PubMed ID: 27771774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b.
    Endo D; Satoh K; Shimada N; Hokari A; Aizawa Y
    World J Gastroenterol; 2017 Apr; 23(13):2355-2364. PubMed ID: 28428715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy.
    Sato A; Ishii T; Adachi K; Kumon D; Tamura T; Noguchi Y; Matsumoto N; Okuse C
    Clin J Gastroenterol; 2016 Apr; 9(2):89-92. PubMed ID: 26896968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.